Herpes Infection Treatment Market (By Product: Therapeutics, Vaccine; By Type: HSV; By Drug; By Route of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Herpes Infection Treatment Market 

5.1. COVID-19 Landscape: Herpes Infection Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Herpes Infection Treatment Market, By Product

8.1. Herpes Infection Treatment Market, by Product, 2022-2030

8.1.1. Therapeutics

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Vaccine

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Herpes Infection Treatment Market, By Type

9.1. Herpes Infection Treatment Market, by Type, 2022-2030

9.1.1. Herpes Simplex

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Herpes Zoster

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Herpes Infection Treatment Market, By Drug 

10.1. Herpes Infection Treatment Market, by Drug, 2022-2030

10.1.1. Acyclovir

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Valacyclovir

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Famciclovir

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Herpes Infection Treatment Market, By Route of Administration

11.1. Herpes Infection Treatment Market, by Route of Administration, 2022-2030

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Topical

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Injection

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Herpes Infection Treatment Market, By Distribution Channel

12.1. Herpes Infection Treatment Market, by Distribution Channel, 2022-2030

12.1.1. Hospital Pharmacy

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Retail Pharmacy

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Online Pharmacy

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Herpes Infection Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.2. Market Revenue and Forecast, by Type (2017-2030)

13.1.3. Market Revenue and Forecast, by Drug (2017-2030)

13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.7. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030) 

13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030) 

13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.10. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.2. Market Revenue and Forecast, by Type (2017-2030)

13.5.3. Market Revenue and Forecast, by Drug (2017-2030)

13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 14. Company Profiles

14.1. Teva Pharmaceutical Industries Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Abbott

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. GlaxoSmithKline plc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Cipla Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly and Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co., Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Novartis AG

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. F. Hoffmann-La Roche Ltd

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms